Skip to content
Credo of the Catholic Laity
  • Home
  • About Us
  • CREDO in the News
  • Events
    • Past Events
    • Audio-Video
    • Calendar
  • News
    • Newsletters
    • Articles
    • Obituaries
    • Subscribe
  • Classifieds
  • Resources
    • Faith
    • Catholic Life
    • Education
    • Pro-Life
    • Tithing
    • Gallery
  • Become a Member
  • Donate
  • Cart
  • Contact Us
  • My account
  • SCANDAL: Catholic Culture of Death
  • Feature Film: NO MERCY – The Catholic Culture of Death

Home » CREDO Forum with Q&A: “COVID-19 Vaccines” What are the Facts? – Sunday, May 2nd at 1pm

  • Share
  • Tweet

COVID-19 Vaccines –  What are the Facts?

Science, Ethics, Fertility, Kids, and Back to School Issues

A CREDO of the Catholic Laity Forum with Q & A
Date: Sunday, May 2nd at 1pm
Location: St. Charles Convention Center, Ballroom, 1st floor
Price: $25 per person

Purchase tickets to the Forum
Pre-register for the Gold Member/Donor Reception to meet the experts

The experts:

Dr. Alan Moy received a bachelor of science in biochemistry at the University of California at Davis. He received an M.D. from Creighton University. He received specialty medical training in Internal Medicine at St. Louis University.  He received his subspecialty training in pulmonary and critical care at the University of Iowa. Dr. Moy was faculty between 1994-2005 and tenured in the Department of Medicine and the Department of Biomedical Engineering at the University of Iowa. Dr. Moy currently maintains an adjunct appointment in the College of Engineering at the University of Iowa. Dr. Moy’s research at the University of Iowa was in the area of vascular biology, inflammation, gene delivery and tissue engineering. His research was supported by the National Institute of Health, the American Heart Association, the American Diabetes Association, and the American Lung Association. In 2005 Dr. Moy left his faculty position to co-found Cellular Engineering Technologies (CET), a pro-life biotech company in Coralville, IA, which manufactures and sells commercial adult stem cells around the globe. In 2006, Dr. Moy founded the John Paul II Stem Cell Research Institute (later renamed the John Paul II Medical Research Institute), a tax-exempt 501-c-3 non-profit research institute devoted toward the use of adult stem cells for treating orphan diseases, degenerative neurological diseases, regenerative medicine and cancer. In 2009 the Small Business Commerce Association selected CET among the Best Business Award in the commercial biotechnology category, which recognizes the top 5 percent of small businesses throughout the country. He has been recognized in the Who’s Who in America and in the Leading Physicians of the World by the International Association of Healthcare Professionals. Dr. Moy’s organizations develop biotechnologies with the objective to displace embryonic stem cells and aborted fetal cells which are ubiquitously used in the pharmaceutical industry for the production of biologics, gene therapy, cell therapy and vaccines.

Sarah Quale is the president of Personhood Alliance Education, the founder of Educe® online learning, and the author of the Foundations online pro-life curriculum. Sarah is an award-winning curriculum and instructional designer, and for the past 20 years, has developed product and sales training for Fortune 500 companies across a broad range of industries. In academia, she created assessment policies, degree programs, and online coursework at the Master’s and PhD levels, focusing on business, education, and psychology disciplines. Sarah is a homeschool advocate and resides with her husband and four children in the Minneapolis, MN, area.

Vidi Aquam
May 2nd – Vaccine Forum: Gold Member/Donor Reception
Help Us Cultivate Catholic Culture
 

New & Upcoming:

  • CREDO Dinner Forum with Q&A featuring Bishop Strickland
  • CREDO Evening Forum with Q&A featuring Hugh Owen
  • Newsletter – Spring 2026

Need Help?

Request Technical Support
Copyright 2026 CREDO of the Catholic Laity
Theme by Colorlib Powered by WordPress
  • Twitter
  • Facebook
Back to top